Worth reading
60In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
150000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Monthly exercise status report for the 12th Series Stock Acquisition Rights issued through a third-party allotment (with an exercise price adjustment clause)
Who receives how much
Number of shares delivered during the relevant month: 150,000 shares (150,000 new shares; no treasury shares transferred)
EVO FUND (issued on 8 December 2025; the number of shares to be allotted is not disclosed in this disclosure)
The lower thin line represents the existing number of shares to which these shares will be added.
発行済株式総数
150,000 shares delivered during the relevant month; 9,164,419 issued shares as of the end of the preceding month (including 2,231 treasury shares)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
The exercise prices in July 2026 were ¥140, ¥156, ¥163, ¥174, ¥178, ¥179 and ¥180. Details of the adjustment clause and the floor price are not disclosed.
Number of Stock Acquisition Rights
Total issued: 60,000 rights; unexercised balance as of the end of the preceding month: 36,800 rights; unexercised balance as of the end of the relevant month: 35,300 rights
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing
Announced on 21 November 2025: issuance through a third-party allotment of new shares, the 12th Series Stock Acquisition Rights (with an exercise price adjustment clause), the 13th Series Stock Acquisition Rights, and the 1st Series Unsecured Ordinary Bonds (private placement to a limited number of investors)
| Item | Details |
|---|---|
| Type of issuance or disposal | Monthly exercise status report for the 12th Series Stock Acquisition Rights issued through a third-party allotment (with an exercise price adjustment clause) |
| Number of shares to be issued or disposed of | Number of shares delivered during the relevant month: 150,000 shares (150,000 new shares; no treasury shares transferred) |
| Intended allottee | EVO FUND (issued on 8 December 2025; the number of shares to be allotted is not disclosed in this disclosure) |
| Dilution Rate | 150,000 shares delivered during the relevant month; 9,164,419 issued shares as of the end of the preceding month (including 2,231 treasury shares) |
| Total number of issued shares | 9,164,419 shares (as of the end of the month preceding the relevant month) → Not disclosed |
| Exercise price | The exercise prices in July 2026 were ¥140, ¥156, ¥163, ¥174, ¥178, ¥179 and ¥180. Details of the adjustment clause and the floor price are not disclosed. |
| Number of Stock Acquisition Rights | Total issued: 60,000 rights; unexercised balance as of the end of the preceding month: 36,800 rights; unexercised balance as of the end of the relevant month: 35,300 rights |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations |
| Most recent equity financing | Announced on 21 November 2025: issuance through a third-party allotment of new shares, the 12th Series Stock Acquisition Rights (with an exercise price adjustment clause), the 13th Series Stock Acquisition Rights, and the 1st Series Unsecured Ordinary Bonds (private placement to a limited number of investors) |
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status of these Stock Acquisition Rights in July 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.